Hospital
UVA Prince William Medical Center
UVA Prince William Medical Center was paid $45.36M by Medicaid between Jan 2018 and Dec 2024, across 265 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoUVA PRINCE WILLIAM MEDICAL CENTER
MANASSAS, VA 20110
MANASSAS, VA 20110
33aNPI1417005760assigned 01/05/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$45.36M
24GClaims845,933
24DCodes billed265
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#18 of 80
Median peer was paid$14.69M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CODER, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,612 | $2.71M | |
| 2019 | 119,668 | $4.03M | |
| 2020 | 96,976 | $3.39M | |
| 2021 | 131,929 | $4.44M | |
| 2022 | 153,793 | $8.37M | |
| 2023 | 145,476 | $12.88M | |
| 2024incomplete | 109,479 | $9.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 36,069 | 32,406 | $8.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 30,832 | 26,974 | $7.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 20,223 | 17,356 | $5.91M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.5% | 11,814 | 9,823 | $2.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 6,928 | 6,203 | $2.15M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 7,344 | 6,342 | $1.68M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 7,772 | 7,070 | $1.57M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 7,633 | 4,569 | $1.38M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.5% | 9,167 | 2,890 | $1.15M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 8,139 | 7,589 | $988K |
| G0378 | Hospital observation service, per hour | 2.2% | 7,998 | 3,452 | $987K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 4,851 | 4,226 | $913K |
253 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,813 | $658K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 8,842 | $466K |
| 0223U | 1.0% | 2,530 | $456K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,422 | $448K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,712 | $447K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,967 | $354K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 551 | $341K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,121 | $325K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 975 | $314K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,968 | $297K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,637 | $277K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,399 | $266K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,245 | $205K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,677 | $194K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 172 | $191K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,769 | $167K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,506 | $156K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,953 | $155K |
| 76830 | Ultrasound, transvaginal | <1% | 1,615 | $151K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,348 | $151K |
| 80053 | Comprehensive metabolic panel | <1% | 38,956 | $147K |
| 76770 | <1% | 834 | $146K | |
| 93971 | <1% | 1,006 | $116K | |
| 70496 | <1% | 272 | $114K | |
| 76642 | <1% | 566 | $109K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,222 | $82K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,650 | $81K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 259 | $78K |
| 76801 | <1% | 1,417 | $72K | |
| 97161 | <1% | 973 | $67K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 99 | $65K |
| J3490 | Unclassified drugs | <1% | 85,602 | $65K |
| 76536 | <1% | 378 | $64K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 604 | $64K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 298 | $63K |
| 93976 | <1% | 276 | $55K | |
| 74018 | <1% | 2,051 | $54K | |
| 72110 | <1% | 826 | $44K | |
| 12001 | <1% | 167 | $44K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,164 | $42K |
| 73564 | <1% | 1,114 | $35K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 297 | $34K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,922 | $34K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,517 | $32K |
| 73030 | <1% | 1,681 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,788 | $30K |
| 73630 | <1% | 1,627 | $30K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 55 | $29K |
| 93975 | <1% | 727 | $29K | |
| 73610 | <1% | 1,761 | $28K | |
| 12011 | <1% | 115 | $28K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 29 | $28K |
| 73562 | <1% | 809 | $27K | |
| 87420 | <1% | 1,370 | $27K | |
| 97165 | <1% | 395 | $26K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 212 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,236 | $25K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 427 | $24K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,849 | $24K |
| 87040 | <1% | 3,336 | $24K | |
| 76870 | <1% | 148 | $24K | |
| 97533 | <1% | 478 | $23K | |
| 92521 | <1% | 66 | $23K | |
| 73130 | <1% | 1,225 | $22K | |
| 92523 | <1% | 120 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40,420 | $19K |
| 72100 | <1% | 629 | $19K | |
| 97162 | <1% | 78 | $18K | |
| 59025 | Fetal non-stress test | <1% | 82 | $18K |
| 77062 | <1% | 168 | $17K | |
| 80143 | <1% | 3,736 | $17K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 65 | $17K |
| 70486 | <1% | 288 | $17K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 79 | $17K |
| 83880 | <1% | 2,329 | $16K | |
| 84484 | <1% | 14,414 | $16K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,222 | $15K |
| 73110 | <1% | 975 | $15K | |
| 80299 | <1% | 3,360 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,106 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,380 | $14K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 4,331 | $13K |
| 93970 | <1% | 54 | $13K | |
| 85379 | <1% | 2,679 | $13K | |
| 90715 | <1% | 579 | $12K | |
| 87631 | <1% | 863 | $11K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 815 | $11K |
| 77066 | Tomosynthesis, mammo | <1% | 225 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,785 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 30 | $11K |
| 73502 | <1% | 467 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,293 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,555 | $10K |
| 71250 | <1% | 126 | $9K | |
| 70491 | <1% | 12 | $9K | |
| 80179 | <1% | 4,501 | $9K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 602 | $9K |
| 85027 | <1% | 8,425 | $9K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 115 | $7K |
| 97166 | <1% | 30 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,748 | $7K |
| 77080 | <1% | 55 | $6K | |
| 70498 | <1% | 271 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $6K |
| 96367 | <1% | 308 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,084 | $5K |
| 73080 | <1% | 359 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,775 | $4K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 130 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,940 | $4K |
| 29125 | <1% | 43 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $4K |
| 87507 | <1% | 36 | $4K | |
| 83605 | <1% | 3,690 | $4K | |
| 83735 | <1% | 10,963 | $4K | |
| 87186 | <1% | 3,515 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 211 | $4K |
| 73140 | <1% | 192 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,231 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,726 | $3K |
| 81001 | <1% | 11,665 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,324 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 793 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,845 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,441 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,830 | $3K |
| 83690 | <1% | 10,072 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 65 | $2K |
| 97116 | <1% | 109 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,078 | $2K |
| 73590 | <1% | 162 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 72131 | <1% | 50 | $2K | |
| 74174 | <1% | 12 | $2K | |
| 87430 | <1% | 3,596 | $2K | |
| 82962 | <1% | 5,631 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,421 | $2K |
| 81025 | <1% | 7,388 | $2K | |
| 85610 | <1% | 4,979 | $2K | |
| 84702 | <1% | 2,774 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,320 | $2K |
| 81003 | <1% | 9,223 | $2K | |
| 84703 | <1% | 7,842 | $2K | |
| 80061 | Lipid panel | <1% | 359 | $2K |
| 74019 | <1% | 66 | $2K | |
| 86140 | <1% | 1,123 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,915 | $1K |
| 87070 | <1% | 4,039 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 214 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,546 | $1K |
| 86850 | <1% | 1,441 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,469 | $1K |
| 73090 | <1% | 181 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,886 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,059 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 27 | $1K |
| 86900 | <1% | 1,831 | $1K | |
| 87486 | <1% | 129 | $1K | |
| 76882 | <1% | 13 | $1K | |
| 86901 | <1% | 2,740 | $959.20 | |
| 96376 | <1% | 5,388 | $958.55 | |
| 87581 | <1% | 115 | $927.88 | |
| 80076 | <1% | 372 | $925.49 | |
| 72040 | <1% | 12 | $845.39 | |
| 72050 | <1% | 14 | $749.74 | |
| 85007 | <1% | 396 | $726.23 | |
| 87634 | <1% | 28 | $693.92 | |
| 72081 | <1% | 14 | $692.42 | |
| 84112 | <1% | 32 | $669.33 | |
| 72070 | <1% | 41 | $615.17 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,227 | $576.87 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,460 | $576.27 |
| 84145 | <1% | 138 | $536.42 | |
| 85652 | <1% | 858 | $507.42 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,055 | $496.50 |
| 87184 | <1% | 1,397 | $485.66 | |
| 86923 | <1% | 21 | $469.70 | |
| 72072 | <1% | 13 | $450.43 | |
| 85730 | <1% | 2,475 | $435.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,159 | $432.28 |
| 84439 | <1% | 108 | $417.77 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,426 | $380.97 |
| 84100 | <1% | 713 | $361.00 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 588 | $352.37 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 74 | $342.32 |
| 88304 | <1% | 220 | $337.59 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,637 | $337.51 |
| 87150 | <1% | 395 | $302.14 | |
| 82550 | <1% | 1,733 | $276.19 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 713 | $258.79 |
| 87210 | <1% | 720 | $255.55 | |
| 97802 | <1% | 12 | $216.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 954 | $211.64 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,601 | $185.56 |
| 82570 | <1% | 104 | $184.22 | |
| 82248 | <1% | 42 | $178.54 | |
| 87081 | <1% | 1,149 | $146.23 | |
| 71101 | <1% | 13 | $134.83 | |
| 87205 | <1% | 454 | $130.60 | |
| A9270 | Non-covered item or service | <1% | 12,942 | $128.96 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 12 | $119.42 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 762 | $110.95 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 795 | $110.87 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 377 | $106.99 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,302 | $103.64 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,571 | $101.69 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 959 | $100.08 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,995 | $93.84 |
| 88342 | <1% | 82 | $85.98 | |
| 87077 | <1% | 449 | $78.59 | |
| 82565 | <1% | 85 | $68.44 | |
| 82803 | <1% | 163 | $59.59 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,196 | $54.33 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,599 | $47.31 |
| 84156 | <1% | 45 | $34.62 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 607 | $34.57 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 241 | $33.46 |
| 82150 | <1% | 124 | $28.39 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 308 | $24.43 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 451 | $20.68 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 505 | $17.46 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 288 | $6.49 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 153 | $5.75 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 136 | $5.72 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 31 | $2.28 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 14 | $1.44 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,512 | $0.86 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 13 | $0.76 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 429 | $0.35 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 721 | $0.00 |
| 94760 | 0% | 19 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 134 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 366 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,336 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 154 | $0.00 |
| C1769 | Guide wire | 0% | 212 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 39 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 35 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 31 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 27 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 20 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 15 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 18 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 273 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 63 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 92 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 352 | $0.00 |
| 82805 | 0% | 73 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 89 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 16 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 28 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 85 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCODER, CHARLES (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.